30-Second Takeaway
- Multilevel interventions with patient education by community health workers improve precision-medicine knowledge and testing.
- PDMP implementation alone did not change immediate postpartum opioid prescribing in this large pre-2016 U.S. cohort.
Week ending May 9, 2026
Selected 2026 briefs: oncology precision care, peripartum opioid policy, genomic consent, trial engagement in pregnancy, and search methods for NMAs
Nonjudgmental, trust-based care facilitated buprenorphine engagement among pregnant/postpartum people of color.
This qualitative analysis interviewed 17 participants of color from seven MOMs trial sites about buprenorphine use in pregnancy and postpartum. Participants reported non-discriminatory, compassionate, and integrated care that countered prior stigma and racism. Trust, transparent communication, flexible scheduling, and frequent personalized encounters facilitated medication initiation and adherence. Findings apply to trial-enrolled pregnant and postpartum people of color and illustrate care practices that supported retention.
Community health worker–led education raised precision-medicine knowledge and testing in underserved oncology patients.
In a randomized trial of 110 low-income, minority adults with cancer, adding a 12-month patient education component improved precision-medicine knowledge versus clinician/payer interventions alone (mean difference 4.17, 95% CI 2.33–7.48; p<0.001). Intervention patients also had higher patient activation and satisfaction. The program reduced emergency visits and hospitalizations and increased receipt of molecular testing and targeted therapy. Results apply to community oncology settings serving low-income, racial/ethnic minority patients.
High consent rates and varied preferences for incidental findings in GBM genomic sequencing.
Among 108 newly diagnosed GBM patients offered whole-exome sequencing, 98.2% consented to genomic analyses. Preferences for incidental findings varied: 31% declined information, 22% wanted actionable findings only, and 42% wanted all information. High participation suggests flexible consent options support enrollment despite potential cognitive impairment risks. Applicability is to trial-based genomic testing in GBM populations.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.